Literature DB >> 26572763

A "new/old method" for TSH stimulation: could a third way to prepare DTC patients for (131)I remnant ablation possibly exist?

Luca Giovanella1, Arnoldo Piccardo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26572763     DOI： 10.1007/s00259-015-3245-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  16 in total

1.  Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?

Authors:  Massimo Salvatori; Germano Perotti; Luca Giovanella; Massimo Eugenio Dottorini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Thyroid lobe ablation with iodine- ¹³¹I in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities.

Authors:  Luca Giovanella; Arnoldo Piccardo; Gaetano Paone; Luca Foppiani; Giorgio Treglia; Luca Ceriani
Journal:  Nucl Med Commun       Date:  2013-08       Impact factor: 1.690

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.

Authors:  Renaud Ciappuccini; Juliette Hardouin; Natacha Heutte; Dominique Vaur; Elske Quak; Jean-Pierre Rame; David Blanchard; Dominique de Raucourt; Stéphane Bardet
Journal:  Eur J Endocrinol       Date:  2014-05-27       Impact factor: 6.664

6.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

7.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

8.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

9.  Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.

Authors:  C J Edmonds; S Hayes; J C Kermode; B D Thompson
Journal:  Br J Radiol       Date:  1977-11       Impact factor: 3.039

10.  Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial.

Authors:  Isabelle Borget; Julia Bonastre; Bogdan Catargi; Désirée Déandréis; Slimane Zerdoud; Daniela Rusu; Stéphane Bardet; Laurence Leenhardt; Delphine Bastie; Claire Schvartz; Pierre Vera; Olivier Morel; Daniele Benisvy; Claire Bournaud; Francoise Bonichon; Antony Kelly; Marie-Elisabeth Toubert; Sophie Leboulleux; Florence Journeau; Ellen Benhamou; Martin Schlumberger
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544
View more
  1 in total

1.  Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

Authors:  Arnoldo Piccardo; Matteo Puntoni; Giulia Ferrarazzo; Luca Foppiani; Gianluca Bottoni; Vania Altrinetti; Giorgio Treglia; Mehrdad Naseri; Bassam Dib; Manlio Cabria; Pierpaolo Trimboli; Michela Massollo; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.